Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02951351 · ClinicalTrials.gov registry record · NA

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

A NA study of Pain, Postoperative and Age-related Macular Degeneration, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT02951351 is a NA study of Pain, Postoperative and Age-related Macular Degeneration that has completed, run by Mayo Clinic. The registered enrollment target is 36 participants, below the 272-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02951351, a NA study of Pain, Postoperative and Age-related Macular Degeneration, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The specific aims of this study are to compare patient experience with and without a proparacaine drop after povidone iodine.

Interventions

  • DRUG Proparacaine
  • PROCEDURE Conjunctival culture

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2016-10-12
Est. Completion 2018-02
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT02951351

The ClinicalTrials.gov registry entry for NCT02951351 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 272-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (87% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Pain, Postoperative appearing as the primary indexed condition, and to 2 interventions - of which Proparacaine is the first listed.

NCT02951351 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02951351 about?

NCT02951351 is a clinical study titled "Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections". The specific aims of this study are to compare patient experience with and without a proparacaine drop after povidone iodine.

What is the current status of trial NCT02951351?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2016-10-12. Estimated completion is 2018-02.

What conditions does trial NCT02951351 study?

This clinical trial studies the following conditions: Pain, Postoperative, Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site Infection, Injection Site.

What interventions are being tested in trial NCT02951351?

The interventions under investigation include: Proparacaine (DRUG), Conjunctival culture (PROCEDURE).

Who is sponsoring clinical trial NCT02951351?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02951351 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain, Postoperative

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.